Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Balasch, J. González-Merlo.
Terapéutica hormonal sustitutiva, ¿la esperanza perdida?.
Prog Obstet Ginecol, 45 (2002), pp. 229-231
[2.]
Writing Group for the Women's Health Initiative Investigators.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial.
Jama, 288 (2002), pp. 321-333
[3.]
C.M. Viscoli, L.M. Brass, W.N. Kernan, P.M. Sarrel, S. Suissa, R.I. Horwitz.
A clinical trial of estrogen-replacement therapy after ischemic stroke.
N Engl J Med, 345 (2001), pp. 1243-1249
[4.]
J.E. Manson, K.A. Martin.
Postmenopausal hormone-replacement therapy.
N Engl J Med, 345 (2001), pp. 34-40
[5.]
D. Grady, D. Herrington, V. Bittner, R. Blumenthal, M. Davidson, M. Hlatky, et al.
Cardiovascular disease outcomes during 6.8 years of hormone therapy. Hearth and estrogen/progestin replacement study follow-up (HERS II).
Jama, 288 (2002), pp. 49-57
[6.]
S. Hulley, C. Furberg, E. Barret-Connor, J. Cauley, D. Grady, W. Haskell, et al.
Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II).
Jama, 288 (2002), pp. 58-66
[7.]
L.L. Humphrey, B.K.S. Chan, H.C. Sox.
Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease.
Ann Intern Med, 137 (2002), pp. 273-284
[8.]
J. Miller, B.K.S. Chan, H.D. Nelson.
Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force.
Ann Intern Med, 136 (2002), pp. 680-690
[9.]
H.D. Nelson, L.L. Humphrey, P. Nygren, S.M. Teutsch, J.D. Allan.
Postmenopausal hormone replacement therapy. Scientific review.
Jama, 288 (2002), pp. 872-881
[10.]
M.A. Hlatky, D. Boothroyd, E. Vittinghoff, P. Sharp, M.A. Whooley.
Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial.
Jama, 287 (2002), pp. 591-597
[11.]
R.A. Mulnard, C.W. Cotman, C. Kawas, C.H. Van Dyck, M. Sano, R. Doody, et al.
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. A randomized controlled trial.
Jama, 283 (2000), pp. 1007-1015
[12.]
Women's Health and Menopause.
A comprehensive Approach. International Position Paper. National Heart, Lung, and Blood Institute Office of Research on Women's Health, National Institutes of Health, (2002),
[13.]
D.B. Petitti.
Hormone replacement therapy for prevention: more evidence, more pessimism.
Jama, 288 (2002), pp. 99-101
[14.]
B. Vastag.
Hormone replacement therapy falls out of favor with expert committee.
Jama, 287 (2002), pp. 1923-1924
[15.]
S.W. Fletcher, G.A. Colditz.
Failure of estrogen plus progesting therapy for prevention.
Jama, 288 (2002), pp. 366-368
[16.]
K.M. Rexrode, J.A. Manson.
Postmenopausal hormone therapy and quality of life. No cause for celebration.
Jama, 287 (2002), pp. 641-642
[17.]
C. Laine.
Postmenopausal hormone replacement therapy: how could we have been so wrong?.
Ann Intern Med, 137 (2001), pp. 290
[18.]
C. Magnusson, I. Persson, H.O. Adami.
More about effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
J Natl Vcancer Inst, 92 (2000), pp. 1183-1184
[19.]
American Society for Reproductive Medicine.
Menopause.
A guide for patients, ASRM, (1936),
[20.]
G.A. Colditz, S.E. Hankinson, D.J. Hunter.
The use of estrogen and progestins and the risk of breast cancer in postmenopausal women.
N Engl J Med, 332 (1995), pp. 1589-1593
[21.]
E.S. LeBlanc, C.M. Viscoli, J.B. Henrich.
Postmenopausal estrogen replacement therapy is associated with adverse breast cancer prognostic indices.
J Womens Health Gen Based Med, 8 (1999), pp. 815-823
[22.]
S. Stallard, J.C. Litherland, C.M. Cordiner, H.M. Dobson, W.D. George, E.A. Mallon, et al.
Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study.
Br Med J, 320 (2000), pp. 348-349
[23.]
R. Fábregas, S. Dexeus.
Factores pronósticos en el cáncer de mama de mujeres con tratamiento hormonal sustitutivo: estudio caso-control. Reunión Anual de la Sociedad Española de Senología, (2000),
[24.]
E. Barret-Connor, D. Goodman-Gruen.
Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women.
Bmj, 311 (1995), pp. 1193-1196
[25.]
E. Barret-Connor.
Heart disease in women.
Fertil Steril, 62 (1994), pp. S127-S132
Copyright © 2002. Sociedad Española de Ginecología y Obstetricia